BIIB:NSD-Biogen Inc (USD)

COMMON STOCK | Drug Manufacturers-General | NSD

Last Closing Price

USD 275.54

Change

+6.10 (+2.26)%

Market Cap

USD 41.46B

Volume

0.81M

Average Target Price

USD 309.09 (+12.18%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaborations with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; Scribe Therapeutics Inc.; Sangamo Therapeutics Inc.; ISD Immunotech; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. Address: 225 Binney Street, Cambridge, MA, United States, 02142

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-25 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AMGN Amgen Inc

+3.60 (+1.42%)

USD147.58B 20.45 12.45
AZN AstraZeneca PLC

+0.76 (+1.43%)

USD140.13B 56.05 18.58
SNY Sanofi

-0.06 (-0.12%)

USD124.49B 25.61 7.41
GILD Gilead Sciences, Inc

+1.22 (+1.82%)

USD83.91B 66.47 21.66
CELG Celgene Corporation

N/A

USD77.04B 13.33 10.62
GRFS Grifols, S.A

-0.07 (-0.37%)

USD17.68B 31.78 17.29
HZNP Horizon Therapeutics Public Li..

+0.78 (+1.00%)

USD17.16B 21.52 30.58
GWPH GW Pharmaceuticals plc

+1.69 (+1.19%)

USD4.04B 91.14 84.16

ETFs Containing BIIB

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

+2.78 (+1.48%)

USD0.48B
DQML Reality Shares Fundstrat .. 0.00 % 0.69 %

N/A

USD2.62M
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.11 (+1.76%)

N/A
WELL:LSE HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.02 (-0.16%)

USD0.02B
VVAL:LSE Vanguard Global Value Fac.. 0.00 % 0.00 %

-0.11 (-0.41%)

USD0.24B
OPEN:LSE iShares Thomson Reuters I.. 0.00 % 0.25 %

-0.08 (-1.26%)

USD0.01B
MOAT:LSE VanEck Vectors Morningsta.. 0.00 % 0.49 %

-0.47 (-1.01%)

USD0.28B
IFSW:LSE iShares Edge MSCI World M.. 0.00 % 0.50 %

-0.04 (-0.47%)

N/A
IFSU:LSE iShares Edge MSCI USA Mul.. 0.00 % 0.35 %

-0.03 (-0.33%)

USD0.11B
FEXU:LSE First Trust US Large Cap .. 0.00 % 0.75 %

-0.33 (-0.54%)

USD0.09B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.08 (+1.07%)

USD0.27B
BIOT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.75 %

N/A

USD8.18M
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.06 (+1.02%)

USD0.19B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.06 (+0.87%)

USD0.27B
AMOM QRAFT AI-Enhanced U.S. La.. 0.00 % 0.75 %

-0.04 (-0.13%)

USD4.81M
ZIG The Acquirers Fund ETF 0.00 % 0.94 %

+0.04 (+0.18%)

USD0.02B
VALQ American Century STOXX U... 0.00 % 0.29 %

+0.12 (+0.27%)

USD0.17B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

+3.59 (+3.52%)

USD0.24B
FFIU Fieldstone UVA Unconstrai.. 0.00 % 0.51 %

+0.04 (+0.15%)

USD0.08B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
VVL:CA Vanguard Global Value Fac.. 0.00 % 0.37 %

-0.01 (-0.03%)

USD0.08B
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

+0.74 (+0.97%)

USD0.26B
ONEO SPDR Russell 1000 Momentu.. 0.00 % 0.20 %

-0.22 (-0.25%)

USD0.25B
LNGR Global X Longevity Themat.. 0.00 % 0.50 %

+0.12 (+0.43%)

USD0.05B
IBB iShares Nasdaq Biotechnol.. 0.00 % 0.47 %

+3.06 (+1.86%)

USD10.37B
FXH First Trust Health Care A.. 0.00 % 0.62 %

+0.37 (+0.33%)

USD1.44B
FTA First Trust Large Cap Val.. 0.00 % 0.60 %

+0.07 (+0.13%)

USD0.76B
FLAG FLAG-Forensic Accounting .. 0.00 % 1.44 %

N/A

USD4.83M
FBT First Trust NYSE Arca Bio.. 0.00 % 0.55 %

+3.63 (+2.01%)

USD2.04B
FAB First Trust Multi Cap Val.. 0.00 % 0.71 %

+0.12 (+0.19%)

USD0.07B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

-0.66 (-3.35%)

USD9.34M
FTGU:XETRA First Trust US Large Cap .. 0.00 % 0.00 %

-0.02 (-0.03%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.53% 75% C 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.53% 75% C 66% D
Trailing 12 Months  
Capital Gain -1.99% 25% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.99% 25% F 31% F
Trailing 5 Years  
Capital Gain 0.83% 25% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.83% 25% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain 1.83% 25% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.83% 25% F 39% F
Risk Return Profile  
Volatility (Standard Deviation) 17.44% 50% F 74% C
Risk Adjusted Return 10.52% 25% F 40% F
Market Capitalization 41.46B 50% F 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 8.87 100% A+ 77% C+
Price/Book Ratio 3.95 75% C 42% F
Price / Cash Flow Ratio 5.86 88% B+ 47% F
EV/EBITDA 6.56 100% A+ 81% B-
Management Effectiveness  
Return on Equity 41.58% 86% B 98% A+
Return on Invested Capital 30.75% 100% A+ 95% A
Return on Assets 15.95% 100% A+ 98% A+
Debt to Equity Ratio 33.42% 88% B+ 54% F
Technical Ratios  
Short Ratio 2.96 38% F 45% F
Short Percent 2.44% 50% F 57% F
Beta 0.51 63% D 85% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.